Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | CHAT | P28329 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9247757 | 0.85 | ALDH1A1 (0.43) | ALDH1A1LMNAL3MBTL1MAPK1TDP1 | |
| SCHEMBL6319705 | 0.84 | ALDH1A1 (0.32) | ALDH1A1CYP2A6 | |
| SCHEMBL17629414 | 0.78 | CYP2C19 (0.41) | ALDH1A1TSHRMAOBCYP2A6LMNA | |
| SCHEMBL3032334 | 0.78 | ALDH1A1 (0.43) | ALDH1A1TSHRMAOBCYP2A6LMNA | |
| SCHEMBL6130600 | 0.78 | CYP2C19 (0.41) | ALDH1A1TSHRMAOBCYP2A6LMNA | |
| SCHEMBL17331000 | 0.78 | ALDH1A1 (0.38) | ALDH1A1TSHRMAOBCYP2A6LMNA | |
| SCHEMBL11880041 | 0.76 | MAPK1 (0.42) | ALDH1A1TSHRMAOBCYP2A6CYP2C19 | |
| SCHEMBL14910046 | 0.76 | MAPK1 (0.42) | ALDH1A1TSHRMAOBCYP2A6CYP2C19 | |
| SCHEMBL2928194 | 0.74 | CYP2A6 (0.48) | TSHRCYP2A6L3MBTL1TDP1RELA | |
| SCHEMBL10519823 | 0.74 | RELA (0.36) | ALDH1A1TSHRMAOBCYP2A6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1864 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109866-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2024-04-04 | — | — | US | claimed |
| EP-4192982-A2 | COMPOSITIONS AND METHODS FOR THE DETECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-2), INFLUENZA A, AND INFLUENZA B | F. Hoffmann-La Roche AG (CH) | 2023-06-14 | — | — | EP | claimed |
| US-20230072538-A1 | METHOD OF MANUFACTURING A SEMICONDUCTOR DEVICE AND PATTERN FORMATION METHOD | TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) | 2023-03-09 | — | — | US | claimed |
| CN-113998707-B | Super-macroporous IRR structure silicate molecular sieve material and preparation method thereof | 南京大学 | 2022-12-27 | — | — | CN | claimed |
| US-20220354949-A1 | NOVEL COMPOUNDS | Xeniopro GmbH (DE) | 2022-11-10 | — | — | US | claimed |
| US-20220042117-A1 | COMPOSITIONS AND METHODS FOR THE SIMULTANEOUS DETECTION OF INFLUENZA A, INFLUENZA B, AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) | ROCHE MOLECULAR SYSTEMS, INC. | 2022-02-10 | — | — | US | claimed |
| CN-113874375-A | Cyclic amide compounds and methods thereof for the treatment of rabies | 株式会社大分大学先端医学研究所 | 2021-12-31 | — | — | CN | claimed |
| WO-2021199037-A1 | METHODS OF DETERMINING ACTIVITY OF ACTIVATED PROTEIN C | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2021-10-07 | — | — | WO | claimed |
| EP-3840834-A2 | AROMATIC MOLECULES FOR USE IN THE TREATMENT OF PATHOLOGICAL CONDITIONS | Xeniopro GmbH (DE) | 2021-06-30 | — | — | EP | claimed |
| EP-3802500-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| US-4968676-A | PLANTS, SOILS, SEEDS | BASF AKTIENGESELLSCHAFT (DE) | 1990-11-06 | — | — | US | claimed |
| US-4897425-A | Fungicidal cyclohexylamines | BASF AKTIENGESELLSCHAFT (DE) | 1990-01-30 | — | — | US | claimed |
| US-4885283-A | Phosphinic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 1989-12-05 | — | — | US | claimed |
| EP-0301873-A2 | 2'-deoxy-5-fluorouridine derivatives | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1989-02-01 | — | — | EP | claimed |
| US-4751073-A | SUNSCREENS | OLIN CORPORATION (US) | 1988-06-14 | — | — | US | claimed |
| EP-0133323-B1 | BENZHYDRYLPIPERAZINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-02-03 | — | — | EP | claimed |
| EP-0191286-A2 | Sebosuppressive cosmetic compositions containing alkoxy or alkylbenzyloxybenzoic acids or salts thereof | Henkel Kommanditgesellschaft auf Aktien (DE) | 1986-08-20 | — | — | EP | claimed |
| EP-0019165-B1 | PROCESS FOR PREPARING 1,3,7-TRIALKYLXANTHINES | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 1985-07-31 | — | — | EP | claimed |
| EP-0133323-A1 | Benzhydrylpiperazines | THE WELLCOME FOUNDATION LIMITED (GB) | 1985-02-20 | — | — | EP | claimed |
| US-4450163-A | ANTIBODY INHIBITORS; N-ALKYLATION OF XANTHINES USING PHASE TRANSFER AGENTS | SOCIETE D'ASSISTANCE TECHNIQUE POUR PRODUITS NESTLE S.A. (CH) | 1984-05-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354949-A1 | NOVEL COMPOUNDS | MUSK, TYR, IKZF3 | ALDH1A1 699/4885TSHR 4349/4885MAOB 3158/4885 |
| US-20240109866-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | ALDH1A1 2977/4885TSHR 102/4885MAOB 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.